Craneware, the Edinburgh-based financial software firm, has said strong new sales have indicated a return to growth.

The company, operating in US healthcare, said it was pleased with the results as it issued trading update for the first half ended 31 December.

It said the increase in new sales reached 30 per cent signalled revenue growth in future periods.

Sales have benefitted from an increased number of contracts being secured, as the company worked through the backlog of contracts delayed from the second half last year.

READ MORE: Craneware chairman to step down after 12 years

Profits are also expected to be up 10% on the first half of the prior year.

The board expects full year results to be in line with forecasts.

Keith Neilson, chief executive, said: "We have been pleased by the strong new sales performance and have seen an indication that sales cycles are shortening, which bodes well for continued sales momentum in the second half of the year.

"This trading performance and progress with the Trisus platform demonstrate the renewed momentum we are experiencing in the business."

READ MORE: Edinburgh technology firm sees shares lump after sales warning

He added: "The ongoing transition to value-based care is a powerful underlying driver for our existing solutions and Trisus platform.

"We are committed to providing our customers with the tools they require to continue to deliver outstanding care to their communities and are passionate about the central role we will play in the ongoing evolution of the US healthcare market.

“The positive sales performance in the first half, combined with our extensive customer base, innovative product offering, high recurring revenues and financial strength, mean the board expects to meet market expectations for the year and is confident in our ability to deliver long-term, sustainable growth.”